Annual CFF
$257.00 K
-$113.00 K-30.54%
December 31, 2023
Summary
- As of February 24, 2025, AVIR annual cash flow from financing activities is $257.00 thousand, with the most recent change of -$113.00 thousand (-30.54%) on December 31, 2023.
- During the last 3 years, AVIR annual CFF has fallen by -$531.49 million (-99.95%).
- AVIR annual CFF is now -99.95% below its all-time high of $531.75 million, reached on December 31, 2020.
Performance
AVIR Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$117.00 K
+$117.00 K+100.00%
September 30, 2024
Summary
- As of February 24, 2025, AVIR quarterly cash flow from financing activities is $117.00 thousand, with the most recent change of +$117.00 thousand (+100.00%) on September 30, 2024.
- Over the past year, AVIR quarterly CFF has increased by +$25.00 thousand (+27.17%).
- AVIR quarterly CFF is now -99.97% below its all-time high of $426.22 million, reached on December 31, 2020.
Performance
AVIR Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$267.00 K
+$25.00 K+10.33%
September 30, 2024
Summary
- As of February 24, 2025, AVIR TTM cash flow from financing activities is $267.00 thousand, with the most recent change of +$25.00 thousand (+10.33%) on September 30, 2024.
- Over the past year, AVIR TTM CFF has increased by +$10.00 thousand (+3.89%).
- AVIR TTM CFF is now -99.95% below its all-time high of $532.23 million, reached on March 31, 2021.
Performance
AVIR TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
AVIR Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -30.5% | +27.2% | +3.9% |
| 3 y3 years | -100.0% | +27.2% | +3.9% |
| 5 y5 years | -99.1% | +27.2% | +3.9% |
AVIR Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -82.5% | at low | -47.5% | -100.0% | -81.8% | +10.3% |
| 5 y | 5-year | -100.0% | -100.0% | -100.0% | +112.8% | -100.0% | +4550.0% |
| alltime | all time | -100.0% | -100.0% | -100.0% | +112.8% | -100.0% | +4550.0% |
Atea Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $117.00 K(>+9900.0%) | $267.00 K(+10.3%) |
| Jun 2024 | - | $0.00(-100.0%) | $242.00 K(0.0%) |
| Mar 2024 | - | $150.00 K(>+9900.0%) | $242.00 K(-5.8%) |
| Dec 2023 | $257.00 K(-30.5%) | $0.00(-100.0%) | $257.00 K(0.0%) |
| Sep 2023 | - | $92.00 K(>+9900.0%) | $257.00 K(-17.6%) |
| Jun 2023 | - | $0.00(-100.0%) | $312.00 K(0.0%) |
| Mar 2023 | - | $165.00 K(>+9900.0%) | $312.00 K(-15.7%) |
| Dec 2022 | $370.00 K | $0.00(-100.0%) | $370.00 K(-27.7%) |
| Sep 2022 | - | $147.00 K(>+9900.0%) | $512.00 K(-55.9%) |
| Jun 2022 | - | $0.00(-100.0%) | $1.16 M(-4.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $223.00 K(+57.0%) | $1.22 M(-16.9%) |
| Dec 2021 | $1.47 M(-99.7%) | $142.00 K(-82.1%) | $1.47 M(-99.7%) |
| Sep 2021 | - | $795.00 K(+1294.7%) | $427.54 M(+0.4%) |
| Jun 2021 | - | $57.00 K(-87.9%) | $425.83 M(-20.0%) |
| Mar 2021 | - | $471.00 K(-99.9%) | $532.23 M(+0.1%) |
| Dec 2020 | $531.75 M(>+9900.0%) | $426.22 M(<-9900.0%) | $531.75 M(+403.9%) |
| Sep 2020 | - | -$913.00 K(-100.9%) | $105.53 M(-0.9%) |
| Jun 2020 | - | $106.45 M(<-9900.0%) | $106.44 M(<-9900.0%) |
| Mar 2020 | - | -$6000.00 | -$6000.00 |
| Dec 2019 | $0.00(-100.0%) | - | - |
| Dec 2018 | $27.48 M | - | - |
FAQ
- What is Atea Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Atea Pharmaceuticals?
- What is Atea Pharmaceuticals annual CFF year-on-year change?
- What is Atea Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Atea Pharmaceuticals?
- What is Atea Pharmaceuticals quarterly CFF year-on-year change?
- What is Atea Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Atea Pharmaceuticals?
- What is Atea Pharmaceuticals TTM CFF year-on-year change?
What is Atea Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of AVIR is $257.00 K
What is the all time high annual CFF for Atea Pharmaceuticals?
Atea Pharmaceuticals all-time high annual cash flow from financing activities is $531.75 M
What is Atea Pharmaceuticals annual CFF year-on-year change?
Over the past year, AVIR annual cash flow from financing activities has changed by -$113.00 K (-30.54%)
What is Atea Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of AVIR is $117.00 K
What is the all time high quarterly CFF for Atea Pharmaceuticals?
Atea Pharmaceuticals all-time high quarterly cash flow from financing activities is $426.22 M
What is Atea Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, AVIR quarterly cash flow from financing activities has changed by +$25.00 K (+27.17%)
What is Atea Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of AVIR is $267.00 K
What is the all time high TTM CFF for Atea Pharmaceuticals?
Atea Pharmaceuticals all-time high TTM cash flow from financing activities is $532.23 M
What is Atea Pharmaceuticals TTM CFF year-on-year change?
Over the past year, AVIR TTM cash flow from financing activities has changed by +$10.00 K (+3.89%)